CommercialCoverageMedium impact
Pharmacy Program Quarterly Update Changes Effective Oct. 1, 2025 – Part 2
BCBS Texas·TX · Endocrinology, Nephrology, Gastroenterology +8 more·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jan 12, 2026
Summary
Blue Cross Blue Shield of Texas is adding 40+ new medications to multiple drug formularies effective October 1, 2025, including new diabetes test strips, specialty drugs for rare diseases, and biosimilar additions. This is Part 2 of the quarterly pharmacy update and does not require member notification. Billing teams should verify that prescribed medications are now covered on the appropriate formulary tier to avoid claim denials and ensure accurate patient cost-sharing calculations.
Action Required
By September 30, 2025: Billing and clinical teams must review the formulary additions and integrate them into practice systems. (1) Update pharmacy benefit management (PBM) software and EMR/EHR systems to reflect new covered medications and their tier assignments across Balanced, Performance, Performance Select, Basic, and Enhanced drug lists. (2) Notify providers prescribing these specialty medications (particularly endocrinologists, nephrologists, gastroenterologists, and neurologists) that these drugs are now covered, especially: KERENDIA (finerenone), OMVOH (mirikizumab), ONAPGO (apomorphine), GOMEKLI (mirdametinib), JOURNAVX (suzetrigine), and VANRAFIA (atrasentan). (3) Update prior authorization workflows if applicable—verify with BCBS TX whether any require prior auth despite being added to formulary. (4) Educate front-desk and billing staff that diabetic test strip coverage has expanded significantly (FreeStyle, Optiumez, Precision brands) to prevent claim denials for patients with diabetes. (5) Billing team should note that naloxone nasal spray 4 mg is now covered as OTC, which may affect claim adjudication logic. Failure to update systems may result in claims being initially denied pending formulary verification, delaying reimbursement.